ReviewInternational journal of nanomedicine2026
Organoid-Derived Extracellular Vesicles: From Biogenesis and Cargo Mechanisms Toward Therapeutic Applications.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organoids are three-dimensional in vitro models that mimic the anatomical and functional complexity of biological tissues, evolving into a powerful platform for studying human development and disease. Organoid-derived extracellular vesicles have been revealed as important intercellular messengers within organoid systems. Participating in the transport of functional substances such as proteins, lipids, and nucleic acids, these lipid-coated nanometer-scale carriers play a role in regulating biological responses. Unlike extracellular vesicles derived from 2D culture, organoid-derived extracellular vesicles carry tissue-specific molecular information and offer unique advantages in terms of targeting precision and biocompatibility. Strategies for engineering organoid-derived extracellular vesicles-such as loading them with specific drugs, surface-modifying them with targeting ligands, or modulating the microenvironment governing vesicle secretion-are currently being extensively explored to enhance their therapeutic potential and targeting capabilities. At the same time, the specific genetic instructions carried by organoid-derived extracellular vesicles hold great promise for early disease diagnosis and prognosis assessment. However, urgent challenges remain, including the heterogeneity of organoids and their in vivo microenvironments, low efficiency in vesicle isolation and purification, and the lack of established standardized production and quality control systems. This paper focuses on two potential applications of organoid-derived extracellular vesicles: as novel therapeutic agents and as tools for improving disease models. It also explores their application prospects in targeted drug delivery, regenerative medicine, and biomarker identification, with the aim of providing insights and guidance for research on the use of organoid-derived extracellular vesicles as multifunctional platforms and carriers in precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.